9D9T
 
 | | Human norovirus GII.4 Sydney protease R112A mutant in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, IODIDE ION, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-21 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DAP
 | | Human norovirus GII.3 protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Genome polyprotein | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.71 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DAJ
 | | Human norovirus GII.4 Sydney protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, IODIDE ION, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DEY
 | |
9DF5
 | |
9DAL
 | | Human norovirus GII.3 R112A mutant protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Peptidase C37 | | Authors: | Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-22 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DA0
 | | Human norovirus GII.4 Houston R112A mutant protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Peptidase C37 | | Authors: | Zhao, B, Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-21 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.28 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9DA7
 | | Human norovirus GII.4 Houston protease in complex with rupintrivir | | Descriptor: | 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER, Peptidase C37 | | Authors: | Zhao, B, Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-21 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
9D9Y
 | | Human norovirus GI.1 Norwalk protease in complex with rupintrivir | | Descriptor: | 3C-like protease, 4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER | | Authors: | Zhao, B, Pham, S.H, Neetu, N, Sankaran, B, Prasad, B.V.V. | | Deposit date: | 2024-08-21 | | Release date: | 2025-02-19 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors.
J.Virol., 99, 2025
|
|
